NPHC's SMA programme, the most structured rare-disease coverage model in the GCC, pairs comprehensive 3-modality access with a GCC-first outcomes-based rebate on Zolgensma.
NPHC's SMA coverage programme is, alongside PNH, the most structured rare-disease programme in Saudi Arabia. Coverage criteria are explicit: SMA Type 1 patients with zero SMN1 copies receive Zolgensma if aged ≤2 years and weighing ≤13.5 kg, or nusinersen/risdiplam otherwise; Type 2/3 patients receive nusinersen or risdiplam; and newborn-screening-identified pre-symptomatic infants (any SMN2 copy count) receive Zolgensma first-line if ≤2 years old. Continuation criteria for chronic therapies require a motor-function assessment every 12 months, with discontinuation triggered by no improvement or a ≥20% decline. Novartis negotiated a GCC Zolgensma price of approximately $1.5-1.8 million one-time, against a US list price of $2.125 million, with a milestone-based rebate if the patient does not achieve independent sitting by 24 months (Type 1/NBS cohort). Gene therapy administration runs through four designated GCC centres: KAMC and KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi, covering an estimated 60-80 annual GCC cases.
Risdiplam (Evrysdi), SFDA- and UAE MOH-registered since 2022, is NPHC-listed for Types 1-3 at an annual GCC WAC of SAR 700,000-800,000, roughly 60-70% of US WAC after tender negotiation, with Roche's GCC rare-disease programme covering home delivery for the oral formulation. Nusinersen costs SAR 350,000-400,000 per injection on a quarterly maintenance schedule, with first-year loading dosing reaching SAR 1.4-1.6 million. Over a Type 2/3 patient's lifetime (diagnosis at age 2 through age 30), cumulative risdiplam therapy cost reaches an estimated SAR 20-25 million, a significant NPHC budget exposure that makes the SMA programme's outcomes-based and continuation-monitoring architecture the reference model other GCC rare-disease programmes are now built to follow.
GCC SMA agent access status — 2026
| Drug (Brand / INN) | SFDA / GCC Registration Status | NPHC / MOH Coverage Pathway | GCC Pricing | Key Access Barrier |
|---|---|---|---|---|
| Zolgensma (onasemnogene abeparvovec) | SFDA 2021; NPHC listed | NPHC covers Type 1 + NBS pre-symptomatic (≤2y, ≤13.5kg) | ~$1.5-1.8M one-time (vs $2.125M US) | Outcomes-based milestone rebate at 24-month motor assessment |
| Evrysdi (risdiplam) | SFDA 2022; MOH UAE 2022 | NPHC listed Types 1-3; 12-month continuation review | ~SAR 700,000-800,000/year (~60-70% of US WAC) | Growing oral-route preference vs nusinersen in Type 2/3 |
Sources: NPHC SMA programme guidelines 2023; Novartis GCC access documentation; NPHC Zolgensma programme documentation 2022; Novartis GCC PSP data; Saudi MOH SMA drug procurement data 2023; NPHC SMA programme budget review.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Full NPHC SMA coverage-criteria matrix by type and modality
- continuation/discontinuation motor-function assessment protocol
- NBS-triggered Zolgensma first-line pathway
Delivers
- Zolgensma GCC pricing and milestone-rebate structure
- precedent analysis for outcomes-based contracting applicability to other high-cost gene therapies (e.g., SCD gene therapy)
Delivers
- Risdiplam vs nusinersen annual and lifetime cost comparison
- NPHC SMA budget exposure modelling and oral-route preference trend among Type 2/3 families
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why NPHC's SMA programme ranks alongside PNH as the most structured rare-disease coverage model in Saudi Arabia
- How the outcomes-based and continuation-monitoring architecture built for SMA is becoming the reference other GCC rare-disease programmes follow
- Exact NPHC criteria: Zolgensma for Type 1 patients aged 2 or under and weighing 13.5kg or less with zero SMN1 copies, nusinersen or risdiplam otherwise
- The newborn-screening pathway giving pre-symptomatic infants, any SMN2 copy count, first-line Zolgensma access if aged 2 or under
- Novartis's negotiated GCC price of $1.5-1.8 million versus the $2.125 million US list price
- How the milestone rebate triggers if a patient does not achieve independent sitting by 24 months
- Annual cost comparison: risdiplam at SAR 700,000-800,000 versus nusinersen's SAR 350,000-400,000 per injection with SAR 1.4-1.6 million first-year loading
- Why cumulative risdiplam cost reaches an estimated SAR 20-25 million over a Type 2/3 patient's lifetime from age 2 through age 30
- How NBS-identified pre-symptomatic infants receive first-line Zolgensma access regardless of SMN2 copy count
- The four designated GCC gene-therapy administration centres: KAMC and KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi
- Modelling NPHC's budget exposure across an estimated 60-80 annual GCC Zolgensma cases plus ongoing risdiplam and nusinersen spend
- The 12-month motor-function assessment protocol that triggers discontinuation on no improvement or a 20% or greater decline
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
This assessment is built from NPHC SMA programme guidelines, Novartis and Roche GCC access documentation, and Saudi MOH drug procurement data.
Key sources: NPHC SMA programme guidelines (2023); Novartis GCC access and Patient Support Programme documentation (2022-2023); Saudi MOH SMA drug procurement data (2023); NPHC SMA programme budget review.
- NPHC coverage and continuation criteria verified against NPHC SMA programme guidelines (2023)
- Zolgensma GCC pricing and milestone-rebate structure verified against Novartis GCC access documentation and NPHC Zolgensma programme documentation (2022)
- Risdiplam and nusinersen cost data verified against Saudi MOH SMA drug procurement data (2023)
- Lifetime cost modelling verified against NPHC SMA programme budget review
Frequently asked questions
Commission this assessment
AXLRx Spinal Muscular Atrophy Payer & HTA (GCC) is built for market access, HEOR, and pricing teams navigating NPHC's comprehensive coverage criteria, Zolgensma's outcomes-based milestone rebate, and chronic-therapy cost modelling across Saudi Arabia, UAE, and Qatar. Custom assessment in 72 hours.
Specify indication, GCC payer focus (NPHC coverage criteria, outcomes-based contracting), and commercial question.
AXLRx analyst confirms GCC market scope (KSA-first or pan-GCC), NPHC coverage analysis, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.